论文部分内容阅读
目的评价不同静脉补铁方法治疗血液透析(MHD)患者肾性贫血的临床疗效。方法采用随机分配法将MHD肾性贫血的42例患者分成两组,每组21例,分别采用静脉端泵后静脉推注蔗糖铁方法,动脉端泵前透析机自带肝素泵泵入蔗糖铁方法治疗。用量均为100mg/次,1次/周,疗程为10周。两组均同时采用常规药促红素(EPO)进行治疗。结果两组患者经治疗后贫血症状均有好转,检查临床指标:血红蛋白(Hb),血清铁蛋白(SF),转铁蛋白饱和度(TSAT)比治疗前明显升高,且差异符合统计学意义(P<0.05)。结论采用静脉端泵后静脉推注蔗糖铁方法,静脉端泵前透析机自带肝素泵泵入蔗糖铁方法治疗血液透析患者肾性贫血效果明显,但静脉端泵前透析机自带肝素泵泵入蔗糖铁方法能减少不良反应发生率,实际操作更方便、安全。
Objective To evaluate the clinical effects of different intravenous iron supplementation on renal anemia in patients with hemodialysis (MHD). Methods Forty-two patients with MHD renal anemia were divided into two groups by random distribution method, 21 cases in each group. Intravenous injection of sucrose solution was performed in venous end. Method of treatment. The dosage was 100mg / time, 1 time / week, treatment for 10 weeks. Both groups were treated with conventional erythropoietin (EPO). Results The symptoms of anemia in both groups improved after treatment. The clinical indexes of hemoglobin (Hb), serum ferritin (SF) and transferrin saturation (TSAT) were significantly higher than those before treatment, and the differences were statistically significant (P <0.05). Conclusion Intravenous end-pump intravenous infusion of sucrose iron method, venous end pump pre-dialysis pump with heparin pump into iron sucrose treatment of hemodialysis patients with renal anemia effect was obvious, but the venous end pump before dialysis machine with heparin pump Iron and sucrose into the method can reduce the incidence of adverse reactions, the actual operation more convenient and safe.